Fluphenazine decanoate injections

Fluphenazine is contraindicated in patients with hematological disease. Hematologic effects including leukopenia, neutropenia, and agranulocytosis have been associated with antipsychotic use. A history of drug-induced leukopenia or neutropenia or pre-existing low white blood cell (WBC) count may increase the likelihood of developing hematologic effects during treatment with an antipsychotic medication. Patients with a history of clinically significant low WBC count or drug-induced leukopenia/neutropenia should have frequent complete blood count (CBC) assessments during the first few months of treatment. Discontinuation of the antipsychotic should be considered if a clinically significant decline in WBC occurs in the absence of an identifiable cause. Patients with clinically significant neutropenia should be closely monitored for fever and infection, and appropriate medical intervention should be instituted if necessary. Fluphenazine should be discontinued in patients with severe neutropenia (ANC < 1000/mm3); ongoing medical care is recommended until the symptoms resolve. Patients with bone marrow suppression secondary to phenothiazine use should not be re-exposed to phenothiazine treatment.

Patient education
• Inform patient that drug may cause dizziness or drowsiness. Advise patient to avoid hazardous tasks that require alertness until CNS response to drug is established.
• Tell patient to avoid ingestion of alcohol and to seek medical approval before taking other drugs.
• Instruct patient to promptly report rash or hives, anxiety, nervousness, anorexia (especially in underweight patients), suspicion of pregnancy, or intent to become pregnant.

The influence of renal impairment on the pharmacokinetics of haloperidol has not been evaluated. About one-third of a haloperidol dose is excreted in urine, mostly as metabolites. Less than 3% of administered haloperidol is eliminated unchanged in the urine. Haloperidol metabolites are not considered to make a significant contribution to its activity, although for the reduced metabolite of haloperidol, back-conversion to haloperidol cannot be fully ruled out. Even though impairment of renal function is not expected to affect haloperidol elimination to a clinically relevant extent, caution is advised in patients with renal impairment, and especially those with severe impairment, due to the long half-life of haloperidol and its reduced metabolite, and the possibility of accumulation (see section ).

Fluphenazine decanoate injections

fluphenazine decanoate injections

Media:

fluphenazine decanoate injectionsfluphenazine decanoate injectionsfluphenazine decanoate injectionsfluphenazine decanoate injectionsfluphenazine decanoate injections

http://buy-steroids.org